Technical Analysis for EFTR - eFFECTOR Therapeutics, Inc.

Grade Last Price % Change Price Change
F 0.00 0.00% 0.00
EFTR closed unchanged on Tuesday, November 19, 2024, on 30 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Down Down Down

Date Alert Name Type % Chg
Boomer Sell Setup Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%

   Recent Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

eFFECTOR Therapeutics, Inc. Description

eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of multiple functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. In addition to the company’s oncology focus, zotatifin is being evaluated as a potential host-directed anti-viral therapy in patients with mild to moderate COVID-19 in collaboration with the University of California, San Francisco, under a $5 million grant sponsored by the Defense Advanced Research Projects Agency.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Cancer Treatment Molecular Biology Breast Cancer Antineoplastic Drugs Lung Cancer Signal Transduction NSCLC Non Small Cell Lung Carcinoma Pembrolizumab Kinase 1

Is EFTR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 20.13
52 Week Low 0.0002
Average Volume 692,862
200-Day Moving Average 8.13
50-Day Moving Average 0.81
20-Day Moving Average 0.05
10-Day Moving Average 0.00
Average True Range 0.05
RSI (14) 14.53
ADX 64.5
+DI 9.44
-DI 49.70
Chandelier Exit (Long, 3 ATRs) 0.17
Chandelier Exit (Short, 3 ATRs) 0.16
Upper Bollinger Bands 0.18
Lower Bollinger Band -0.09
Percent B (%b) 0.33
BandWidth 585.84
MACD Line -0.24
MACD Signal Line -0.31
MACD Histogram 0.0639
Fundamentals Value
Market Cap 683.33
Num Shares 3.42 Million
EPS -18.75
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 54.16
Price-to-Book 13.38
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.00
Resistance 3 (R3) 0.00 0.00 0.00
Resistance 2 (R2) 0.00 0.00 0.00 0.00
Resistance 1 (R1) 0.00 0.00 0.00 0.00 0.00
Pivot Point 0.00 0.00 0.00 0.00 0.00
Support 1 (S1) 0.00 0.00 0.00 0.00 0.00
Support 2 (S2) 0.00 0.00 0.00 0.00
Support 3 (S3) 0.00 0.00 0.00
Support 4 (S4) 0.00